scholarly journals Comparative effectiveness of radiotherapy for early‐stage hormone receptor‐positive breast cancer in elderly women using real‐world data

2018 ◽  
Vol 8 (1) ◽  
pp. 117-127 ◽  
Author(s):  
Askal A. Ali ◽  
Rima Tawk ◽  
Hong Xiao ◽  
Ellen Campbell ◽  
Anastasia Semykina ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Real World ◽  
Hormone Receptor ◽  
Comparative Effectiveness ◽  
Elderly Women ◽  
Early Stage ◽  
Real World Data ◽  
World Data ◽  
Hormone Receptor Positive ◽  
Positive Breast Cancer

Real world data of trastuzumab in the treatment of early stage HER- 2 positive breast cancer in southern of Brazil

The Breast ◽  
2019 ◽  
Vol 44 ◽  
pp. S56
Author(s):  
T. Belladona Cardoso ◽  
J.D. Lyra Batista ◽  
R.J. Vargas Alves ◽  
K. Arima Tiscoski ◽  
F. Pontes Grando
Keyword(s):  
Breast Cancer ◽  
Real World ◽  
Early Stage ◽  
Real World Data ◽  
World Data ◽  
Her 2 ◽  
Positive Breast Cancer

CDK4/6 inhibitors and hormone therapy in hormone receptor-positive advanced breast cancer: Real-world data and intrinsic subtypes defined by PAM50.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e13035-e13035
Author(s):  
Tamara Diaz Redondo ◽  
Rocío Lavado-Valenzuela ◽  
Maria Emilia Dominguez-Recio ◽  
Sofía Ruíz ◽  
Encarnación González Flores ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
Advanced Breast Cancer ◽  
Hormone Therapy ◽  
Real World ◽  
Hormone Receptor ◽  
Advanced Breast ◽  
Real World Data ◽  
World Data ◽  
Hormone Receptor Positive

e13035 Background: CDK 4/6 inhibitors plus hormone therapy(HT) has been approved by FDA and EMA for the treatment of hormone receptor positive HER2 negative advanced breast cancer (HR+/HER2-BC) with improvement in PFS consistently demonstrated in several clinical trials. Benefit in OS has also been demonstrated in Monaleesa3 and Monarch2 clinical trials. To date we don`t have real-world data and no single biomarker has been validated to identify subgroups that would benefit most from this new drugs. Methods: This is a multicenter, real life, observational study. From January 2015 to December 2019 we recruited 98 patients with immunohistochemical(IHC) HR+/HER2-BC treated with CDK4-6 inhibitor plus HT. All patients were classified into intrinsic molecular subtypes based on PAM50 signature done centrally in diagnostic/metastatic biopsies. Results: The clinical and treatment characteristic are in table. In IHC studies all population were classified as luminalA (40%) and LuminalB (60%) but we found HER2 enriched patients (6%) defined by PAM50. The median PFS for all population was 14 months and median PFS for Luminal A subtype was 12 months and 15 months for Luminal B with no statistically significant differences between them. Conclusions: Based on the results obtained, the intrinsic molecular subtype defined by PAM50 does not appear to be associated with differences in PFS in our study group. However, a study with a larger number of patients would be necessary. Inhibitors of CDK4/6, have established a central role in the management of HR+/HER2-BC. There is a clear benefit in PFS and OS but we still don’t know which patients will benefit from this therapy and who will not while the side effects such chronic neutropenia, QTC prolongation and diarrhea could have a negative impact on their quality of life. Its mandatory to explore a good biomarker to direct therapy. [Table: see text]

Survival Outcomes of Early-Stage Hormone Receptor-Positive Breast Cancer in Elderly Women

2020 ◽  
Vol 27 (12) ◽  
pp. 4853-4860 ◽  
Author(s):  
Apoorve Nayyar ◽  
Paula D. Strassle ◽  
Kathleen Iles ◽  
Danielle Jameison ◽  
Jihane Jadi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
Elderly Women ◽  
Early Stage ◽  
Survival Outcomes ◽  
Hormone Receptor Positive ◽  
Positive Breast Cancer

scholarly journals Endocrine Therapy in Premenopausal Hormone Receptor–Positive Breast Cancer

2016 ◽  
Vol 12 (11) ◽  
pp. 1148-1156 ◽  
Author(s):  
Amye J. Tevaarwerk ◽  
Kari B. Wisinski ◽  
Ruth M. O’Regan
Keyword(s):  
Breast Cancer ◽  
Endocrine Therapy ◽  
Systemic Therapy ◽  
Hormone Receptor ◽  
Randomized Trials ◽  
Early Stage ◽  
Premenopausal Women ◽  
Breast Cancers ◽  
Hormone Receptor Positive ◽  
Positive Breast Cancer

Systemic therapy for premenopausal women with hormone receptor–positive breast cancer has evolved in the last 5 years, but critical questions remain. Recent randomized trials have demonstrated a benefit for the addition of ovarian suppression to endocrine therapy in patients with breast cancers considered to be at high risk for recurrence, whereas those with lower-risk cancers seem to have a favorable outcome with tamoxifen alone. Two large randomized trials have demonstrated a benefit for extending adjuvant tamoxifen beyond 5 years. Currently the choice of systemic therapy is selected empirically but molecular profiling may, in the near future, provide a more conclusive means of selecting an endocrine therapeutic approach for premenopausal patients. Given that a significant subset of hormone receptor–positive cancers are intrinsically resistant to endocrine agents, as well as the finding that inhibiting cyclin-dependent kinases 4 and 6 and mammalian target of rapamycin appears to potentially reverse this resistance in patients with metastatic disease, evaluation of these agents in the early-stage setting is ongoing.

Sign in / Sign up

Export Citation Format

Share Document